Published in Rev Med Liege on January 01, 1999
Significant effects of mild endogenous hormonal changes in humans: considerations for low-dose testing. Environ Health Perspect (2001) 0.90
[The epidemic of metabolic diseases, a major problem of public health]. Rev Med Liege (1999) 0.78
[Clinical study of the month. Prolonged insulin independence after transplantation of islets of Langerhans in a patient with type 1 diabetes: achievement of a dream?]. Rev Med Liege (2000) 0.77
[Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"]. Rev Med Liege (1999) 0.76
[Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study]. Rev Med Liege (1999) 0.76
[Antioxidant vitamins in the prevention of cardiovascular diseases. First part: epidemiologic studies]. Rev Med Liege (2000) 0.75
[Drug of the month. Torasemide (Torrem)]. Rev Med Liege (1994) 0.75
[Drug-clinics. The hue and cry over central appetite suppressants!]. Rev Med Liege (1997) 0.75
[Therapeutic update 1997-1998]. Rev Med Liege (1998) 0.75
[Lamotrigine (Lamictal)]. Rev Med Liege (1997) 0.75
[Drug clinics. How I treat a patient with a low concentration of HDL cholesterol]. Rev Med Liege (1998) 0.75
[Multiple endocrine neoplasms: medical therapy]. Rev Med Liege (1993) 0.75
[Clinical case of the month. Prolonged spontaneous remission of a typical type 1 diabetes]. Rev Med Liege (1995) 0.75
[On the inapplicability of certain therapeutic guidelines in practice: the example of reimbursement for hypolipidemic agents in Belgium]. Rev Med Liege (2000) 0.75
[Study of the month. Long-term (1-2 years) clinical trials with orlistat, a new drug for the treatment of obesity]. Rev Med Liege (1999) 0.75
[Clinical study of the month. The LIPID study: "long-term intervention with pravastatin in ischaemic disease"]. Rev Med Liege (1999) 0.75
[Drug of the month. fosinopril (Fosinil)]. Rev Med Liege (1994) 0.75
[Pharma-clinics. Drug of the month. Tacrine (Cognex)]. Rev Med Liege (1996) 0.75
[How I explore... insulin resistance in clinical practice]. Rev Med Liege (1996) 0.75
[Pharma-clinics. Doping with erythropoietin or the misuse of therapeutic advances]. Rev Med Liege (1998) 0.75
[Pharma-clinics. Drug of the month. Tramadol (Dolzam)]. Rev Med Liege (1996) 0.75
[How I investigate the new criteria for the diagnosis of diabetes mellitus]. Rev Med Liege (1997) 0.75
[Could homeopathy find its legitimacy in the "positive" results of a meta-analysis?]. Rev Med Liege (1997) 0.75
[Pharmaco-economics of hypolipidemic agents: analysis of factors influencing the cost-effectiveness relation]. Rev Med Liege (1998) 0.75
[Image of the month. What collapse!]. Rev Med Liege (1998) 0.75
[Therapeutic update 1997-1998 (1). First part]. Rev Med Liege (1998) 0.75
[Drug of the month. Fluvastatin (Lescol)]. Rev Med Liege (1997) 0.75
[How I treat... an obese patient with type 2 diabetes]. Rev Med Liege (1994) 0.75
[The unstable diabetic patient: from physiopathology to treatment]. Rev Med Liege (1995) 0.75
[Pharmaclinics. Drug of the month. Captopril (Capoten) in diabetic nephropathies]. Rev Med Liege (1995) 0.75
[Current therapeutic agents 1995-1996]. Rev Med Liege (1996) 0.75
[Drug of the month. Lacidipine (Motens)]. Rev Med Liege (1994) 0.75
[From obesity to diabetes or the natural history of abnormalities in the secretion and action of insulin]. Rev Med Liege (1992) 0.75
[How I explore.... an adult subject with suspected hypothyroidism]. Rev Med Liege (1996) 0.75
[Evidence-based medicine. Input of controlled clinical trials]. Rev Med Liege (2000) 0.75
[Pharma-clinics. How I treat... A patient with orthostatic hypotension]. Rev Med Liege (1997) 0.75
[Drug of the month. Paroxetine (Seroxar, Aropax)]. Rev Med Liege (1994) 0.75
[How I diagnose... anorexia nervosa]. Rev Med Liege (1995) 0.75
[Pharma-clinics. Drug of the month. Fluticasone propionate (Flixotide)]. Rev Med Liege (1996) 0.75
[Drug of the month. Lansoprazole (DakaR)]. Rev Med Liege (1995) 0.75
[Hypoglycemic sulfamides, 50 years after Loubatiere]. Rev Med Liege (1996) 0.75
[Lessons from the "United Kingdom Prospective Diabetes Study"]. Rev Med Liege (1998) 0.75
[Pharma-clinics. Medication of the month. Glimepiride (Amarylle)]. Rev Med Liege (2000) 0.75
[Clinical study of the month. After DCCT, the EDIC study]. Rev Med Liege (2000) 0.75
[Estrogen therapy after menopause and cardiovascular protection: discordance between epidemiologic observations and the results of therapeutic trials] . Rev Med Liege (2000) 0.75
[How I explore... a patient with orthostatic hypotension]. Rev Med Liege (1997) 0.75
[Pharma-clinics. Medication of the month. Moxonidine (Moxon)]. Rev Med Liege (2000) 0.75
[Drug of the month. Moclobemide (Aurorix)]. Rev Med Liege (1994) 0.75
[Drug-clinics. The drug of the month. Imitrex nasal spray (sumatriptan)]. Rev Med Liege (1997) 0.75